Pancreatic Cancer Research

ResearcherInha UniversityActive in the last 2 years

Kyung Hee Jung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1291-0461; OpenAlex author ID A5020025516. Sources: OpenAlex.

Their work

Papers
23 (first author 11, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 23

  1. Repositioning of aripiprazole, an anti‑psychotic drug, to sensitize the chemotherapy of pancreatic cancer. Co-author DOI 10.3892/ijmm.2024.5458↗
  2. Taurine Synthesis by 2-Aminoethanethiol Dioxygenase as a Vulnerable Metabolic Alteration in Pancreatic Cancer. Co-author DOI 10.4062/biomolther.2024.086↗
  3. Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4062/biomolther.2024.029↗
  4. Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2023.114716↗
  5. Discovery of a novel NUAK1 inhibitor against pancreatic cancer. First author DOI 10.1016/j.biopha.2022.113241↗
  6. A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes. Co-author DOI 10.1093/jnci/djab191↗
  7. Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. Co-author DOI 10.4062/biomolther.2021.145↗
  8. A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer. First author PMID 36225647↗
  9. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. Co-author DOI 10.1016/j.canlet.2021.03.015↗
  10. An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer. First author DOI 10.3390/cancers11020155↗
  11. A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.03.041↗
  12. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.09.013↗
  13. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. First author DOI 10.1159/000491058↗
  14. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.03.009↗
  15. Corrigendum to "Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer" [Cancer Lett. 396 (201… Co-author DOI 10.1016/j.canlet.2017.06.019↗
  16. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. First author DOI 10.18632/oncotarget.22850↗
  17. HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. First author DOI 10.18632/oncotarget.12871↗
  18. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. First author DOI 10.1016/j.canlet.2014.07.001↗
  19. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. First author DOI 10.18632/oncotarget.2363↗
  20. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2435↗
  21. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. First author DOI 10.1016/j.canlet.2013.01.007↗
  22. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer. First author DOI 10.1016/j.canlet.2013.04.002↗
  23. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. First author DOI 10.3892/or.2013.2517↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Soon‐Sun Hong · 18 shared papers, 2013–2025 · strength 1.73
  2. Hong Hua Yan · 16 shared papers, 2013–2022 · strength 1.04
  3. Mi Kwon Son · 13 shared papers, 2013–2022 · strength 0.82
  4. Zhenghuan Fang · 9 shared papers, 2014–2022 · strength 0.67
  5. Soyeon Ko · 4 shared papers, 2022–2025 · strength 0.65
  6. Soon‐Sun Hong · 4 shared papers, 2014–2025 · strength 0.59
  7. Jung Hee Park · 7 shared papers, 2016–2022 · strength 0.58
  8. Yeo Wool Kang · 6 shared papers, 2017–2022 · strength 0.52
  9. Ye Jin Cho · 3 shared papers, 2022–2025 · strength 0.50
  10. Sungwoo Hong · 7 shared papers, 2013–2022 · strength 0.50
  11. Woohyung Lee · 2 shared papers, 2022–2025 · strength 0.39
  12. Sunghyouk Park · 2 shared papers, 2022–2025 · strength 0.39
  13. Hoonsik Nam · 2 shared papers, 2022–2025 · strength 0.39
  14. Ji Eun Lee · 5 shared papers, 2017–2021 · strength 0.38
  15. Yong‐Sung Kim · 3 shared papers, 2018–2022 · strength 0.31
  16. Dae Ui Lee · 1 shared paper, 2024 · strength 0.31
  17. Ji Eun Lee · 2 shared papers, 2022–2023 · strength 0.29
  18. Song Cheol Kim · 1 shared paper, 2025 · strength 0.27
  19. Minhee Park · 1 shared paper, 2025 · strength 0.22
  20. Ye-Lim Ryu · 4 shared papers, 2013–2014 · strength 0.16
  21. Myeong-Seong Seo · 1 shared paper, 2022 · strength 0.15
  22. Chae‐Ok Yun · 2 shared papers, 2017 · strength 0.14
  23. Marufa Rumman · 2 shared papers, 2016–2018 · strength 0.13
  24. Soo‐Youl Kim · 1 shared paper, 2022 · strength 0.13
  25. Song Cheol Kim · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.